A Phase 3 interventional study of CHOP and rituximab [MabThera/Rituxan] in Lymphoma, Large B-Cell, Diffuse, sponsored by Hoffmann-La Roche. Completed at 186 sites in 27 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-10-11.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies testing cyclophosphamide in Lymphoma, Large B-Cell, Diffuse — 11 open to participants now, 20 under way, 1 of them phase 3. Cyclophosphamide · Lymphoma, Large B-Cell, Diffuse.
Among the 109 studies testing cyclophosphamide in Lymphoma, Large B-Cell, Diffuse, this one is the 4th largest by enrollment of the 99 interventional ones that give a count, is one of 2 that started in 2012, is one of 7 in phase 3, and was the 69th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →11 of the 109 studies testing cyclophosphamide in Lymphoma, Large B-Cell, Diffuse are open now, in 12 countries. Recruiting first, the newest first:
The First Hospital of Jilin University · Sites in China
Ages 65+
University of Washington · Sites in United States
Ages 18+
Allogene Therapeutics · Sites in United States, Australia, Canada and 1 more country
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 68 · Phase 3 8 · Phase 4 3
First in 1988; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 572 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 44 across the 99 interventional studies. Of the 75 that completed or were terminated, 31 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 109 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
28 studies in Lymphoma, Large B-Cell, Diffuse by Hoffmann-La Roche: 2 open now, 5 under way, 1 of them phase 3. Of 22 finished, 13 (59%) have results posted.
Among the 28 studies in Lymphoma, Large B-Cell, Diffuse by Hoffmann-La Roche, this one is the 4th largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2012, is one of 7 in phase 3, and was the 5th registered.
Hoffmann-La Roche’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2005.
4 of the studies testing cyclophosphamide in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT02153580City of Hope Medical CenterCellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | 2027-08-11 |
| NCT03125642Masonic Cancer Center, University of MinnesotaAuto Stem Cell Transplant for Lymphoma Patients | 2027-09-30 |
| NCT04002947National Cancer Institute (NCI)Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | 2027-10-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 109 studies testing cyclophosphamide in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Hoffmann-La Roche’s 28 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
This multicenter, randomized, open label parallel-group study will evaluate the efficacy and safety of subcutaneous versus intravenous MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy in patients with previously untreated CD20-positive diffuse large B-Cell lymphoma. Patients will be randomized to receive either MabThera/Rituxan 1400 mg subcutaneously or MabThera/Rituxan 375 mg/m2 intravenously on Day 1 of each cycle for 8 cycles, in combination with 6-8 cycles of CHOP chemotherapy. Anticipated time on study treatment is 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CHOP · Drug: rituximab [MabThera/Rituxan]
Drug: CHOP · Drug: rituximab [MabThera/Rituxan]
Drug pages: Cyclophosphamide · Doxorubicin · Vincristine · Prednisone
CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
Drug page: Rituximab
The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
Drug page: Rituximab
375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu)
Tumor response was assessed per criteria published by Cheson et al (1999). According to consensus recommendations, CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by greater than (\>) 75 percent (%) but still \>1.5 centimeters (cm) in size, and indeterminate bone marrow assessment. The percentage of participants with either response at the end of induction (EOI) was determined with corresponding 95% Pearson-Clopper confidence interval (CI).
Time frame: Up to approximately 4.25 years
Cancer Treatment Satisfaction Questionnaire (CTSQ) Domain Scores
The CTSQ is a validated 16-item questionnaire that measures three domains related to satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.
Time frame: At Cycle 7 (each cycle was 14 or 21 days)
Rituximab Administration Satisfaction Questionnaire (RASQ) Domain Scores
The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.
Time frame: At Cycle 7 (each cycle was 14 or 21 days)
Median Duration of Rituximab Administration for Each Treatment Cycle
Duration of rituximab administration was defined as the time from start to end of the SC injection or IV infusion. The median duration was reported.
Time frame: Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days)
Percentage of Participants by Time Spent in the Infusion Chair/Bed for Each Treatment Cycle
Chair time was defined as the amount of time the participant occupied an infusion chair/bed for a single treatment cycle of rituximab + CHOP chemotherapy. Where the chair time was not documented for a given cycle, it was reported as "Missing".
Time frame: Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days)
Percentage of Participants by Time Spent in the Hospital for Each Treatment Cycle
Hospital time was defined as the amount of time the participant was in the hospital for the course of one cycle of rituximab + CHOP chemotherapy. Where the hospital time was not documented for a given cycle, it was reported as "Missing".
Time frame: Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days)
Number of Participants With an Event-Free Survival (EFS) Event
EFS events included disease progression, relapse, initiation of other anti-lymphoma therapy, or death. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as greater than or equal to (≥) 50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
Time frame: Up to approximately 4.25 years
Duration of EFS
EFS was defined as the time from randomization to first occurrence of disease progression, relapse, initiation of other anti-lymphoma therapy, or death, whichever occurred first. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as a ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
Time frame: Up to approximately 4.25 years
Number of Participants With Relapse or Death at the Time of Primary Analysis
Tumor response was assessed according to criteria published by Cheson et al (1999). Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu. The number of participants who had experienced relapse or death prior to the clinical cut-off date (October 2014) was determined.
Time frame: Up to approximately 2 years (assessed at Baseline, Day 1 of each cycle [maximum 8 cycles; each cycle was 14 or 21 days], every 3 months thereafter, and/or 4 weeks after early termination)
Duration of Disease-Free Survival (DFS)
DFS was defined as the time from date of initial CR/CRu to the date of relapse or death from any cause. Tumor response was assessed according to criteria published by Cheson et al (1999). Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
Time frame: Up to approximately 4.25 years
Number of Participants With Progression, Relapse, or Death
Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
Time frame: Up to approximately 4.25 years
Duration of Progression-Free Survival (PFS)
PFS was defined as the time from randomization to first occurrence of disease progression, relapse, or death from any cause. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
Time frame: Up to approximately 4.25 years
Number of Deaths
Time frame: Up to approximately 4.25 years
Duration of Overall Survival (OS)
OS was defined as the time from randomization to death from any cause.
Time frame: Up to approximately 4.25 years
| Milestone | Rituximab Subcutaneous (SC) | Rituximab Intravenous (IV) |
|---|---|---|
| Started | 369 | 203 |
| Completed | 230 | 125 |
| Not completed | 139 | 78 |
| Withdrew: Withdrawal by subject | 14 | 14 |
| Withdrew: Protocol violation | 4 | 4 |
| Withdrew: Treatment failure | 1 | 1 |
| Withdrew: Death | 69 | 34 |
| Withdrew: Stable or progressed disease | 5 | 3 |
| Withdrew: Lost to follow-up | 20 | 16 |
| Withdrew: Lack of compliance | 6 | 1 |
| Withdrew: Other | 20 | 5 |
Tumor response was assessed per criteria published by Cheson et al (1999). According to consensus recommendations, CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by greater than (\>) 75 percent (%) but still \>1.5 centimeters (cm) in size, and indeterminate bone marrow assessment. The percentage of participants with either response at the end of induction (EOI) was determined with corresponding 95% Pearson-Clopper confidence interval (CI).
| percentage of participants | Rituximab SC | Rituximab IV |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Complete Response Unconfirmed (CRu) | 50.6 (45.2 to 56.0) | 42.4 (35.0 to 50.0) |
The CTSQ is a validated 16-item questionnaire that measures three domains related to satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.
| units on a scale | Rituximab SC | Rituximab IV |
|---|---|---|
| Expectations of Therapy (n=280,141) | 79.35 ± 17.422 | 82.94 ± 16.536 |
| Feelings about Side Effects (n=276,141) | 60.69 ± 21.594 | 57.62 ± 23.339 |
| Satisfaction with Therapy (n=278,141) | 85.92 ± 11.428 | 83.60 ± 13.451 |
The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.
| units on a scale | Rituximab SC | Rituximab IV |
|---|---|---|
| Physical Impact (n=278,140) | 86.24 ± 14.012 | 81.49 ± 16.848 |
| Psychological Impact (n=277,141) | 85.65 ± 13.920 | 78.65 ± 18.233 |
| Impact on ADLs (n=266,140) | 83.77 ± 16.117 | 57.38 ± 19.230 |
| Convenience (n=279,143) | 82.32 ± 13.428 | 60.14 ± 17.473 |
| Satisfaction (n=282,141) | 89.58 ± 12.051 | 77.39 ± 18.232 |
Duration of rituximab administration was defined as the time from start to end of the SC injection or IV infusion. The median duration was reported.
| hours | Rituximab SC | Rituximab IV |
|---|---|---|
| Cycle 1 (n=346,190) | 4.0 (0.10 to 11.00) | 4.0 (1.20 to 10.00) |
| Cycle 2 (n=361,178) | 0.1 (0.10 to 23.10) | 3.0 (0.50 to 10.00) |
| Cycle 3 (n=349,177) | 0.1 (0.10 to 5.50) | 2.8 (1.00 to 21.40) |
| Cycle 4 (n=346,173) | 0.1 (0.00 to 2.50) | 2.7 (0.50 to 8.00) |
| Cycle 5 (n=332,165) | 0.1 (0.00 to 2.50) | 2.6 (0.10 to 8.10) |
| Cycle 6 (n=319,162) | 0.1 (0.00 to 2.50) | 2.7 (0.10 to 20.00) |
| Cycle 7 (n=304,156) | 0.1 (0.00 to 23.60) | 2.7 (0.50 to 6.70) |
| Cycle 8 (n=305,152) | 0.1 (0.00 to 2.50) | 2.55 (0.10 to 17.90) |
| Overall (n=368,201) | 4.7 (0.10 to 28.70) | 19.00 (1.20 to 57.40) |
Chair time was defined as the amount of time the participant occupied an infusion chair/bed for a single treatment cycle of rituximab + CHOP chemotherapy. Where the chair time was not documented for a given cycle, it was reported as "Missing".
| percentage of participants | Rituximab SC | Rituximab IV |
|---|---|---|
| Less than 30 minutes (Cycle 1) | 0 | 0 |
| 30 minutes to 1 hour (Cycle 1) | 0 | 0.5 |
| 1 to 2 hours (Cycle 1) | 1.4 | 0 |
| 2 to 4 hours (Cycle 1) | 20.6 | 17.2 |
| 4 to 12 hours (Cycle 1) | 69.4 | 72.4 |
| More than 12 hours (Cycle 1) | 7.3 | 7.9 |
| Missing (Cycle 1) | 1.4 | 2.0 |
| Less than 30 minutes (Cycle 2) | 7.3 | 0 |
| 30 minutes to 1 hour (Cycle 2) | 2.4 | 0 |
| 1 to 2 hours (Cycle 2) | 17.1 | 1.1 |
| 2 to 4 hours (Cycle 2) | 56.1 | 36.2 |
| 4 to 12 hours (Cycle 2) | 12.2 | 60.1 |
| More than 12 hours (Cycle 2) | 0.3 | 1.1 |
| Missing (Cycle 2) | 4.6 | 1.6 |
| Less than 30 minutes (Cycle 3) | 5.6 | 0 |
| 30 minutes to 1 hour (Cycle 3) | 2.0 | 0 |
| 1 to 2 hours (Cycle 3) | 22.1 | 0.5 |
| 2 to 4 hours (Cycle 3) | 55.9 | 38.9 |
| 4 to 12 hours (Cycle 3) | 12.6 | 58.4 |
| More than 12 hours (Cycle 3) | 0.3 | 0.5 |
| Missing (Cycle 3) | 1.7 | 1.6 |
| Less than 30 minutes (Cycle 4) | 5.1 | 0 |
| 30 minutes to 1 hour (Cycle 4) | 2.8 | 0 |
| 1 to 2 hours (Cycle 4) | 21.8 | 1.1 |
| 2 to 4 hours (Cycle 4) | 55.0 | 36.7 |
| 4 to 12 hours (Cycle 4) | 13.9 | 60.6 |
| More than 12 hours (Cycle 4) | 0.3 | 0.6 |
| Missing (Cycle 4) | 1.1 | 1.1 |
| Less than 30 minutes (Cycle 5) | 5.0 | 0.6 |
| 30 minutes to 1 hour (Cycle 5) | 2.4 | 0 |
| 1 to 2 hours (Cycle 5) | 25.2 | 1.1 |
| 2 to 4 hours (Cycle 5) | 53.4 | 40.2 |
| 4 to 12 hours (Cycle 5) | 12.8 | 56.3 |
| More than 12 hours (Cycle 5) | 0 | 0.6 |
| Missing (Cycle 5) | 1.2 | 1.1 |
| Less than 30 minutes (Cycle 6) | 3.4 | 0.6 |
| 30 minutes to 1 hour (Cycle 6) | 3.1 | 0 |
| 1 to 2 hours (Cycle 6) | 23.0 | 1.8 |
| 2 to 4 hours (Cycle 6) | 56.7 | 42.5 |
| 4 to 12 hours (Cycle 6) | 12.3 | 53.3 |
| More than 12 hours (Cycle 6) | 0 | 0 |
| Missing (Cycle 6) | 1.5 | 1.8 |
| Less than 30 minutes (Cycle 7) | 18.7 | 0 |
| 30 minutes to 1 hour (Cycle 7) | 7.0 | 0 |
| 1 to 2 hours (Cycle 7) | 26.9 | 4.9 |
| 2 to 4 hours (Cycle 7) | 40.2 | 48.8 |
| 4 to 12 hours (Cycle 7) | 6.0 | 44.4 |
| More than 12 hours (Cycle 7) | 0 | 0 |
| Missing (Cycle 7) | 1.3 | 1.9 |
| Less than 30 minutes (Cycle 8) | 20.3 | 0.6 |
| 30 minutes to 1 hour (Cycle 8) | 6.4 | 0 |
| 1 to 2 hours (Cycle 8) | 29.3 | 4.4 |
| 2 to 4 hours (Cycle 8) | 36.7 | 50.9 |
| 4 to 12 hours (Cycle 8) | 5.8 | 43.4 |
| More than 12 hours (Cycle 8) | 0 | 0 |
| Missing (Cycle 8) | 1.6 | 0.6 |
Hospital time was defined as the amount of time the participant was in the hospital for the course of one cycle of rituximab + CHOP chemotherapy. Where the hospital time was not documented for a given cycle, it was reported as "Missing".
| percentage of participants | Rituximab SC | Rituximab IV |
|---|---|---|
| Less than 2 hours (Cycle 1) | 0.3 | 0 |
| 2 to 4 hours (Cycle 1) | 3.0 | 1.5 |
| 4 to 6 hours (Cycle 1) | 19.8 | 20.7 |
| 6 to 12 hours (Cycle 1) | 39.0 | 43.8 |
| 12 to 24 hours (Cycle 1) | 8.9 | 6.9 |
| More than 24 hours (Cycle 1) | 26.8 | 24.1 |
| Missing (Cycle 1) | 2.2 | 3.0 |
| Less than 2 hours (Cycle 2) | 3.8 | 0 |
| 2 to 4 hours (Cycle 2) | 33.1 | 10.1 |
| 4 to 6 hours (Cycle 2) | 27.9 | 33.5 |
| 6 to 12 hours (Cycle 2) | 16.3 | 38.8 |
| 12 to 24 hours (Cycle 2) | 3.8 | 1.1 |
| More than 24 hours (Cycle 2) | 10.3 | 11.7 |
| Missing (Cycle 2) | 4.9 | 4.8 |
| Less Than 2 hours (Cycle 3) | 3.6 | 0.5 |
| 2 to 4 hours (Cycle 3) | 37.2 | 11.9 |
| 4 to 6 hours (Cycle 3) | 30.2 | 30.8 |
| 6 to 12 hours (Cycle 3) | 14.5 | 41.6 |
| 12 to 24 hours (Cycle 3) | 2.8 | 2.2 |
| More than 24 hours (Cycle 3) | 9.8 | 10.3 |
| Missing (Cycle 3) | 2.0 | 2.7 |
| Less Than 2 hours (Cycle 4) | 4.5 | 0 |
| 2 to 4 hours (Cycle 4) | 36.3 | 10.0 |
| 4 to 6 hours (Cycle 4) | 27.5 | 31.1 |
| 6 to 12 hours (Cycle 4) | 17.6 | 42.2 |
| 12 to 24 hours (Cycle 4) | 2.0 | 2.8 |
| More than 24 hours (Cycle 4) | 10.2 | 10.6 |
| Missing (Cycle 4) | 2.0 | 3.3 |
| Less Than 2 hours (Cycle 5) | 5.0 | 0.6 |
| 2 to 4 hours (Cycle 5) | 39.5 | 11.5 |
| 4 to 6 hours (Cycle 5) | 26.4 | 34.5 |
| 6 to 12 hours (Cycle 5) | 16.0 | 37.4 |
| 12 to 24 hours (Cycle 5) | 2.1 | 1.7 |
| More than 24 hours (Cycle 5) | 8.9 | 10.9 |
| Missing (Cycle 5) | 2.1 | 3.4 |
| Less Than 2 hours (Cycle 6) | 4.3 | 0.6 |
| 2 to 4 hours (Cycle 6) | 39.6 | 12.6 |
| 4 to 6 hours (Cycle 6) | 26.4 | 34.1 |
| 6 to 12 hours (Cycle 6) | 16.3 | 38.3 |
| 12 to 24 hours (Cycle 6) | 2.5 | 2.4 |
| More than 24 hours (Cycle 6) | 8.6 | 9.0 |
| Missing (Cycle 6) | 2.5 | 3.0 |
| Less Than 2 hours (Cycle 7) | 17.7 | 0 |
| 2 to 4 hours (Cycle 7) | 40.8 | 23.5 |
| 4 to 6 hours (Cycle 7) | 19.9 | 36.4 |
| 6 to 12 hours (Cycle 7) | 10.4 | 30.9 |
| 12 to 24 hours (Cycle 7) | 2.8 | 2.5 |
| More than 24 hours (Cycle 7) | 5.7 | 3.7 |
| Missing (Cycle 7) | 2.5 | 3.1 |
| Less Than 2 hours (Cycle 8) | 18.0 | 0 |
| 2 to 4 hours (Cycle 8) | 40.5 | 25.8 |
| 4 to 6 hours (Cycle 8) | 21.9 | 34.0 |
| 6 to 12 hours (Cycle 8) | 8.7 | 30.8 |
| 12 to 24 hours (Cycle 8) | 2.6 | 1.3 |
| More than 24 hours (Cycle 8) | 5.8 | 5.0 |
| Missing (Cycle 8) | 2.6 | 3.1 |
EFS events included disease progression, relapse, initiation of other anti-lymphoma therapy, or death. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as greater than or equal to (≥) 50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
| participants | Rituximab SC | Rituximab IV |
|---|---|---|
| Number of Participants With an Event-Free Survival (EFS) Event | 116 | 53 |
EFS was defined as the time from randomization to first occurrence of disease progression, relapse, initiation of other anti-lymphoma therapy, or death, whichever occurred first. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as a ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
| months | Rituximab SC | Rituximab IV |
|---|---|---|
| Duration of EFS | NA (NA to NA) | NA (NA to NA) |
Tumor response was assessed according to criteria published by Cheson et al (1999). Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu. The number of participants who had experienced relapse or death prior to the clinical cut-off date (October 2014) was determined.
| participants | Rituximab SC | Rituximab IV |
|---|---|---|
| Number of Participants With Relapse or Death at the Time of Primary Analysis | 12 | 5 |
DFS was defined as the time from date of initial CR/CRu to the date of relapse or death from any cause. Tumor response was assessed according to criteria published by Cheson et al (1999). Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
| months | Rituximab SC | Rituximab IV |
|---|---|---|
| Duration of Disease-Free Survival (DFS) | NA (NA to NA) | NA (NA to NA) |
Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
| participants | Rituximab SC | Rituximab IV |
|---|---|---|
| Number of Participants With Progression, Relapse, or Death | 95 | 38 |
PFS was defined as the time from randomization to first occurrence of disease progression, relapse, or death from any cause. Tumor response was assessed according to criteria published by Cheson et al (1999). Progression was defined as ≥50% increase in the sum of products of greatest diameters of any previously identified abnormal lymph node or the appearance of any new lesion. Relapse was defined as a new lesion or increase by ≥50% in size of previously involved sites, or ≥50% increase in greatest diameter of any previously identified node \>1 cm, following an earlier assessment of CR or CRu.
| months | Rituximab SC | Rituximab IV |
|---|---|---|
| Duration of Progression-Free Survival (PFS) | NA (NA to NA) | NA (NA to NA) |
| participants | Rituximab SC | Rituximab IV |
|---|---|---|
| Number of Deaths | 56 | 22 |
OS was defined as the time from randomization to death from any cause.
| months | Rituximab SC | Rituximab IV |
|---|---|---|
| Duration of Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
Collected over Up to approximately 4.25 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab SC | — | 155/369 (42%) | 319/369 (86.4%) |
| Rituximab IV | — | 77/203 (37.9%) | 172/203 (84.7%) |
| Event | Rituximab SC | Rituximab IV |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 49/369 | 24/203 |
| PneumoniaInfections and infestations | 27/369 | 7/203 |
| NeutropeniaBlood and lymphatic system disorders | 22/369 | 10/203 |
| PyrexiaGeneral disorders | 7/369 | 3/203 |
| LeukopeniaBlood and lymphatic system disorders | 1/369 | 3/203 |
| Septic shockInfections and infestations | 3/369 | 3/203 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/369 | 3/203 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/369 | 3/203 |
| Atrial fibrillationCardiac disorders | 2/369 | 3/203 |
| Cardiac arrestCardiac disorders | 1/369 | 3/203 |
| Event | Rituximab SC | Rituximab IV |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 104/369 | 54/203 |
| AnaemiaBlood and lymphatic system disorders | 88/369 | 40/203 |
| AlopeciaSkin and subcutaneous tissue disorders | 87/369 | 48/203 |
| NauseaGastrointestinal disorders | 79/369 | 47/203 |
| Neutrophil count decreasedInvestigations | 81/369 | 43/203 |
| FatigueGeneral disorders | 71/369 | 29/203 |
| ConstipationGastrointestinal disorders | 56/369 | 34/203 |
| Lymphocyte count decreasedInvestigations | 53/369 | 20/203 |
| DiarrhoeaGastrointestinal disorders | 52/369 | 20/203 |
| White blood cell count decreasedInvestigations | 51/369 | 23/203 |
Safety Population: All participants who received at least one dose of study drug according to treatment received.
| Age, Continuous(years) | Rituximab SC | Rituximab IV | Total |
|---|---|---|---|
| Mean | 60.4 ± 13.78 | 61.0 ± 12.63 | 60.6 ± 13.38 |
| Sex: Female, Male(Participants) | Rituximab SC | Rituximab IV | Total |
|---|---|---|---|
| Female | 165 | 100 | 265 |
| Male | 204 | 103 | 307 |
Showing the first 100 of 186 sites across 27 countries. Choose a country and city above to see the rest.
Ran from Aug 2012 to primary completion in Oct 2014, 25 months.
Results were first posted in Feb 2016, 1 year 3 months after primary completion.
Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 25 months is below that.
Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Doxorubicin · Vincristine · Prednisone · Rituximab
Lymphoma, Large B-Cell, Diffuse →